Looking for reliable medications to treat 'Chronic Myeloid Leukemia'? This page offers a detailed resource for the most up-to-date treatment options, including both generic and brand-name medications.

Researchers are exploring new treatment options for chronic myeloid leukemia (CML ... Remission means you don’t have any signs or symptoms of cancer on your tests. Allogenic stem cell transplant ...

When Aaron von Freter learned he had chronic myeloid leukemia (CML), he “felt like the room was spinning,” he remembers. “I thought I’d been served a death sentence.” Aaron was 45 years old and had no ...

and acute myeloid leukemia (AML). Chronic leukemias may grow for years before causing symptoms. Types of chronic leukemia include chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML ...

Medically reviewed by Gagandeep Brar, MD Leukemias and lymphomas are often grouped together because they are both blood-related cancers that originate in lymphocytes. However, leukemia originates in ...

Two other types of leukemia -- acute myeloid leukemia (AML) and chronic myeloid leukemia (CML ... you might not notice any symptoms for years. A routine blood test might be the first clue ...

Acquired miR-142 deficit in leukemic stem cells has been associated with chronic myeloid leukemia blast crisis. Here the authors show that acquired miR-142 deficit in T cells further enables ...

If you've been diagnosed with CML, or chronic myelogenous leukemia, you know that your bone marrow is making cells from early versions of certain blood cells. Your treatment will be geared toward ...

Blast crisis (BC) is the final deadly phase of chronic myeloid leukemia (CML), but its molecular basis remains poorly understood. Here, we show that CML BC is regulated by calcium-calmodulin ...

Suboptimal response or treatment failure to standard-dose imatinib are relevant problems in chronic-phase chronic myeloid leukemia patients. Insufficient adherence is one of the main causes of ...

Various clinical trials have evaluated the clinical value of an initial dose intensification of imatinib in CML-CP patients (an overview of the most important response rates is given in Table 1).